Biocon to start selling breast cancer drug in India in February

MUMBAI Sat Jan 18, 2014 3:34pm IST

Kiran Mazumdar-Shaw, Chairman and Managing Director of Biocon Ltd, speaks during the Reuters India Investment Summit in Bangalore December 6, 2007. REUTERS/Arko Datta/Files

Kiran Mazumdar-Shaw, Chairman and Managing Director of Biocon Ltd, speaks during the Reuters India Investment Summit in Bangalore December 6, 2007.

Credit: Reuters/Arko Datta/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - Biocon Ltd(BION.NS) said its generic version of Roche's(ROG.VX) Herceptin breast cancer treatment would be available to patients in India from the first week of February.

Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with U.S.-based Mylan Inc.

About 150,000 people are diagnosed with breast cancer every year in India, of which 25 percent are eligible for treatment with trastuzumab, Biocon said.

Roche decided not to pursue a patent application for its breast cancer drug Herceptin in India, paving the way for generic drugmakers to produce cheaper copies, known as biosimilars because they are not identical to the original drug.

Global sales for Herceptin were valued at about $6.4 billion in 2012, including about $21 million in India, Biocon said.

(Reporting by Aradhana Aravindan; Editing by Sonya Hepinstall)

FILED UNDER:

Diplomacy

Reuters Showcase

Microfinance

Microfinance

Funding the unfunded: India helps small business borrow to grow  Full Article 

Insurance Sector

Insurance Sector

UK healthcare firm Bupa sees strong growth in India  Full Article 

Sensex Rises

Sensex Rises

Sensex edges up; consumer and healthcare stocks rise  Full Article 

Market Eye

Market Eye

FTSE adds nine Indian firms as large-caps in Asia-Pacific ex-Japan index   Full Article 

Udwin Interview

Udwin Interview

Society created Delhi gang rape convicts: Filmmaker Leslee Udwin  Full Article 

China Economy

China Economy

China signals "new normal" with lower annual growth target  Full Article 

E-commerce

E-commerce

China backs e-commerce expansion in win for Alibaba, JD.com  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage